LRP4-IgG service line testing in seronegative myasthenia gravis and controls



      LRP4 is a post-synaptic membrane protein that promotes acetylcholine (AChR) clustering on the crest of post-synaptic neuromuscular folds. Autoantibodies against LRP4 are suggested to account for myasthenia gravis (MG) patients negative for antibodies to AChR.


      To report a clinical experience with service-line LRP4-IgG cell-based testing in electrodiagnostically confirmed MG patients and controls.


      We identified all Mayo patients undergoing MG evaluations with send out LRP4-IgG antibody testing by cell-based assay, having clinical-electrodiagnostic (EDX) testing. To be included, muscle acetylcholine receptor binding (AChR-Bi) and muscle-specific tyrosine kinase (MuSK) antibodies had to be absent prior to LRP4-IgG testing. Follow-up AChR-Bi antibody testing was reviewed. Also tested for LRP4-IgGs were 119 healthy subjects.


      Identified were 25 generalized MG, 24 ocular MG, and 55 patients initially considered to have MG prior to negative EDX testing. No seronegative patients with EDX confirmed MG had LRP4-IgG positivity but five non-MG patients did: Guillain-Barre syndrome with fatigue (N = 1); multiple cranial neuropathies (N = 1); functional neurologic disorders (N = 3). Of healthy subjects, 4% (5/119) were LRP4-IgG positive (N = 5) or had a borderline result (N = 1). Of MG patients with repeat AChR-Bi testing, 40% (10/25) seroconverted (5 with ocular MG and 5 with generalized MG) (median AChR IgG value: 0.34 nmol/L, range 0.2–20.9 nmol/L, median followup 26 months, range 2–72 months).


      Clinical review of LRP4-IgG commercial cell-based testing suggests lack of diagnostic utility in seronegative EDX-confirmed MG. The clinical utility of LRP4-IgG testing is not substantiated in service line testing. In contrast, repeat testing for AChR-Bi antibodies is shown clinically useful.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Neuroimmunology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Chan K.H.
        • Lachance D.H.
        • Harper C.M.
        • Lennon V.A.
        Frequency of seronegativity in adult-acquired generalized myasthenia gravis.
        Muscle Nerve. 2007; 36: 651-658
        • Engel A.G.
        • Shen X.M.
        • Selcen D.
        • Sine S.M.
        Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment.
        Lancet Neurol. 2015; 14: 461
        • Haven T.R.
        • Astill M.E.
        • Pasi B.M.
        • Carper J.B.
        • Wu L.L.
        • Tebo A.E.
        • et al.
        An algorithm for acetylcholine receptor antibody testing in patients with suspected myasthenia gravis.
        Clin. Chem. 2010; 56: 1028-1029
        • Higuchi O.
        • Hamuro J.
        • Motomura M.
        • Yamanashi Y.
        Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis.
        Ann. Neurol. 2011; 69: 418-422
        • Hoch W.
        • McConville J.
        • Helms S.
        • Newsom-Davis J.
        • Melms A.
        • Vincent A.
        Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.
        Nat. Med. 2001; 7: 365-368
        • Howard Jr., F.M.
        • Lennon V.A.
        • Finley J.
        • Matsumoto J.
        • Elveback L.R.
        Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis.
        Ann. N. Y. Acad. Sci. 1987; 505: 526-538
        • Lazaridis K.
        • Tzartos S.J.
        Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics.
        Front. Immunol. 2020; 11: 212
        • Li Y.
        • Zhang Y.
        • Cai G.
        • He D.
        • Dai Q.
        • Xu Z.
        • et al.
        Anti-LRP4 autoantibodies in Chinese patients with myasthenia gravis.
        Muscle Nerve. 2017; 56: 938-942
        • Nicolau S.
        • Milone M.
        The electrophysiology of presynaptic congenital myasthenic syndromes with and without facilitation: from electrodiagnostic findings to molecular mechanisms.
        Front. Neurol. 2019; 10: 257
        • Pevzner A.
        • Schoser B.
        • Peters K.
        • Cosma N.C.
        • Karakatsani A.
        • Schalke B.
        • et al.
        Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis.
        J. Neurol. 2012; 259: 427-435
        • Rivner M.H.
        • Quarles B.M.
        • Pan J.X.
        • Yu Z.
        • Howard Jr., J.F.
        • Corse A.
        • et al.
        Clinical features of LRP4/agrin-antibody-positive myasthenia gravis: a multicenter study.
        Muscle Nerve. 2020; 62: 333-343
        • Shelly S.
        • Paul P.
        • Bi H.
        • Dubey D.
        • Milone M.
        • Sorenson E.J.
        • et al.
        Improving accuracy of myasthenia gravis autoantibody testing by reflex algorithm.
        Neurology. 2020; 95: e3002-e3011
        • Shelly S.
        • Mills J.R.
        • Dubey D.
        • McKeon A.
        • Zekeridou A.
        • Pittock S.J.
        • et al.
        Clinical utility of striational antibodies in paraneoplastic and myasthenia gravis paraneoplastic panels.
        Neurology. 2021; 96 (24): e2966-e2976
        • Stalberg E.
        • Sanders D.B.
        • Ali S.
        • Cooray G.
        • Leonardis L.
        • Loseth S.
        • et al.
        Reference values for jitter recorded by concentric needle electrodes in healthy controls: a multicenter study.
        Muscle Nerve. 2016; 53: 351-362
        • Tzartos J.S.
        • Zisimopoulou P.
        • Rentzos M.
        • Karandreas N.
        • Zouvelou V.
        • Evangelakou P.
        • et al.
        LRP4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients.
        Ann. Clin. Transl. Neurol. 2014; 1: 80-87
        • Wang J.
        • Xiao Y.
        • Zhang K.
        • Luo B.
        • Shen C.
        Introducing autoimmunity at the synapse by a novel animal model of experimental autoimmune myasthenia gravis.
        Neuroscience. 2018; 374: 264-270
        • Zisimopoulou P.
        • Evangelakou P.
        • Tzartos J.
        • Lazaridis K.
        • Zouvelou V.
        • Mantegazza R.
        • et al.
        A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis.
        J. Autoimmun. 2014; 52: 139-145